[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Alhalaweh et al., 2010 - Google Patents

Formation of cocrystals from stoichiometric solutions of incongruently saturating systems by spray drying

Alhalaweh et al., 2010

View PDF
Document ID
9464341703447110801
Author
Alhalaweh A
Velaga S
Publication year
Publication venue
Crystal growth & design

External Links

Snippet

Spray drying is a well established technique for material processing and scale-up. This study investigated the formation of pharmaceutical cocrystals by spray drying. The cocrystal formation mechanisms in spray-drying and solution methods, based on triangular phase …
Continue reading at pstorage-acs-6854636.s3.amazonaws.com (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide

Similar Documents

Publication Publication Date Title
Alhalaweh et al. Formation of cocrystals from stoichiometric solutions of incongruently saturating systems by spray drying
Laitinen et al. Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability
Wu et al. Transformations between co-amorphous and co-crystal systems and their influence on the formation and physical stability of co-amorphous systems
Lu et al. Preparation and characterization of theophylline− nicotinamide cocrystal
Löbmann et al. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen
Ueda et al. Application of a salt coformer in a co-amorphous drug system dramatically enhances the glass transition temperature: a case study of the ternary system carbamazepine, citric acid, and l-arginine
Xie et al. Improved release of celecoxib from high drug loading amorphous solid dispersions formulated with polyacrylic acid and cellulose derivatives
Laitinen et al. Emerging trends in the stabilization of amorphous drugs
Fung et al. Physical stability and dissolution behavior of ketoconazole–organic acid coamorphous systems
Berry et al. Applying hot-stage microscopy to co-crystal screening: A study of nicotinamide with seven active pharmaceutical ingredients
Remenar et al. Celecoxib: nicotinamide dissociation: using excipients to capture the cocrystal's potential
Pagire et al. Spherical crystallization of carbamazepine/saccharin co-crystals: Selective agglomeration and purification through surface interactions
Weyna et al. Synthesis and structural characterization of cocrystals and pharmaceutical cocrystals: mechanochemistry vs slow evaporation from solution
Alhalaweh et al. Solubility behavior and solution chemistry of indomethacin cocrystals in organic solvents
Shevchenko et al. Diversity in itraconazole cocrystals with aliphatic dicarboxylic acids of varying chain length
Shayanfar et al. Drug–drug coamorphous systems: characterization and physicochemical properties of coamorphous atorvastatin with carvedilol and glibenclamide
Ullah et al. The development of carbamazepine-succinic acid cocrystal tablet formulations with improved in vitro and in vivo performance
Bag et al. Screening and selective preparation of polymorphs by fast evaporation method: a case study of aspirin, anthranilic acid, and niflumic acid
Alhalaweh et al. Effects of polymer and surfactant on the dissolution and transformation profiles of cocrystals in aqueous media
Bookwala et al. Preparation of a crystalline salt of indomethacin and tromethamine by hot melt extrusion technology
Paudel et al. Relating hydrogen-bonding interactions with the phase behavior of naproxen/PVP K 25 solid dispersions: evaluation of solution-cast and quench-cooled films
Padrela et al. Insight into the mechanisms of cocrystallization of pharmaceuticals in supercritical solvents
Thipparaboina et al. Ionic, neutral, and hybrid acid–base crystalline adducts of lamotrigine with improved pharmaceutical performance
Chow et al. Stability of pharmaceutical cocrystal during milling: a case study of 1: 1 caffeine–glutaric acid
Yan et al. Crystal structures, stability, and solubility evaluation of two polymorphs of a 2: 1 melatonin–piperazine cocrystal